Roche (SIX: RO, ROG; OTCQX: RHHBY) is set to present new 48-week data on its investigational Bruton’s tyrosine kinase (BTK) inhibitor, fenebrutinib, at the 40th Congress of the European Committee…
Interim results from the ongoing IDeate-Lung01 phase 2 trial show that ifinatamab deruxtecan (I-DXd) continues to deliver promising objective response rates in patients with pretreated extensive-stage small cell lung cancer…
Stolen contact lenses sold through fake online pharmacies, prescription medications missing active ingredients, and surgical sutures made from substandard materials are just a few examples of counterfeit healthcare products that…
Eli Lilly and Company (NYSE: LLY) has announced positive results from two phase 3 clinical trials, QWINT-1 and QWINT-3, evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2…
Eli Lilly and Company (NYSE: LLY) and EVA Pharma have announced a new partnership aimed at increasing access to baricitinib for an estimated 20,000 individuals across 49 low- and middle-income…
Daiichi Sankyo Europe (Daiichi Sankyo) has reaffirmed its commitment to addressing unmet needs and barriers in cardiovascular (CV) care by highlighting disparities in treatment and outcomes among different patient groups.…
Fresenius Kabi, a division of Fresenius, and the Association for the Advancement of Blood & Biotherapies (AABB) are excited to announce the commencement of the 19th annual Blood Collectors Week,…
Daiichi Sankyo Europe (Daiichi Sankyo) has reinforced its commitment to addressing unmet needs and disparities in cardiovascular care by emphasizing the differences in treatment and outcomes among diverse patient groups.…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the results from its Phase 3 PALISADE study, which investigated the efficacy of the drug plozasiran in patients with familial chylomicronemia syndrome (FCS).…
Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society…
The NBI-‘568-SCZ2028 dose-finding study successfully met its primary endpoint with the once-daily 20 mg dose. This dose showed a significant and clinically meaningful reduction in the Positive and Negative Syndrome…
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory…